Abstract: A homogeneous sweetener composition containing aspartame having tasting properties similar to sucrose is disclosed. Also are disclosed process of manufacture and use thereof.
FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENT RULES, 2003
PROVISIONAL SPECIFICATION
(See Section 10 and Rule 13)
Title of the invention:
Neotame based tow cost sweetener
Applicant: EnSigns Health Care Pvt. Ltd
32 Prachi Residency,
Baner Road, Pune411045,
Maharashtra, India
The following specification describes the invention
FIELD OF THE INVENTION
The present invention relates generally to formulations of artificial sweetening agents and more particularly to such characterized by low cost while maintaining all other properties desired in conventional sweetening agents.
BACKGROUND OF THE PRESENT INVENTION
Neotame is an artificial sweetener which is a derivative of the dipeptide composed of the amino acids, aspartic acid and phenylalanine and that is between 8,000 and 13,000 times sweeter than sucrose (table sugar) and its molecular formula may be represented as:
Neotame
Considering the high sweetness index and chemical stability of Neotame, it may be blended with other
sweetening agents to achieve subsequent benefits. This has been the focus of research of the
present inventor.
Commercial production of cane sugar (sucrose) is expensive. Factors including machinery, raw
material, pre and post manufacture processes, logistics and their upkeep cumulatively add to the
market price of sugar.
Moreover, the sugar industry is season specific and is subject to success of the sugarcane crop.
Being a perishable commodity, such sugar cannot be stored for indefinite periods and thus, has
depreciative market value compared vis-a-vis the storage time.
Thus, there is a pressing need for sweetening agents which are effective in their intended purpose
and can yet be made available at low costs to the consumer.
The following brief description provides a brief outline of the present invention.
BRIEF DESCRIPTION OF THE INVENTION
In accordance with principles of the present invention, the present disclosure is directed towards product compositions as specified in Table 1.
# Low cost sugar ingredient (10%) Filler ingredient (90%)
1 Neotame Sucrose
2
Hi maltose corn syrup
3
Invert sugar
4
Fructose oligosaccharide
5
Sorbitol
Table 1: Product compositions
Although this invention has been illustrated by reference to specific embodiments, it will be apparent to those skilled in the art that various changes and modifications may be made which clearly fall within the scope of the invention.
Rohit Deshpande.
[Agent for applicant; registration number IN/PA-1389]
Dated this 25th Day of March 2009
| Section | Controller | Decision Date |
|---|---|---|
| # | Name | Date |
|---|---|---|
| 1 | 745-MUM-2009-ABSTRACT(29-9-2009).pdf | 2018-08-10 |
| 1 | 745MUM2009_reply to ER.pdf | 2018-08-10 |
| 2 | 745-MUM-2009-CLAIMS(29-9-2009).pdf | 2018-08-10 |
| 2 | 745MUM2009_CS.pdf | 2018-08-10 |
| 3 | 745-MUM-2009_EXAMREPORT.pdf | 2018-08-10 |
| 3 | 745-MUM-2009-CORRESPONDENCE(26-9-2009).pdf | 2018-08-10 |
| 4 | 745-MUM-2009-FORM 5(29-9-2009).pdf | 2018-08-10 |
| 4 | 745-MUM-2009-CORRESPONDENCE(IPO)-(26-8-2009).pdf | 2018-08-10 |
| 5 | 745-mum-2009-form 3.pdf | 2018-08-10 |
| 5 | 745-MUM-2009-CORRESPONDENCE(IPO)-(FER)-(10-1-2014).pdf | 2018-08-10 |
| 6 | 745-mum-2009-form 26.pdf | 2018-08-10 |
| 6 | 745-MUM-2009-CORRESPONDENCE(IPO)-(HEARING NOTICE)-(30-8-2016).pdf | 2018-08-10 |
| 7 | 745-mum-2009-form 2.pdf | 2018-08-10 |
| 7 | 745-MUM-2009-DESCRIPTION(COMPLETE)-(29-9-2009).pdf | 2018-08-10 |
| 8 | 745-mum-2009-form 2(title page).pdf | 2018-08-10 |
| 9 | 745-mum-2009-description(provisional).pdf | 2018-08-10 |
| 9 | 745-MUM-2009-FORM 2(TITLE PAGE)-(PROVISIONAL)-(30-3-2009).pdf | 2018-08-10 |
| 10 | 745-mum-2009-form 1.pdf | 2018-08-10 |
| 10 | 745-MUM-2009-FORM 2(TITLE PAGE)-(29-9-2009).pdf | 2018-08-10 |
| 11 | 745-MUM-2009-FORM 18(29-6-2011).pdf | 2018-08-10 |
| 12 | 745-mum-2009-form 2(29-9-2009).pdf | 2018-08-10 |
| 13 | 745-MUM-2009-FORM 18(29-6-2011).pdf | 2018-08-10 |
| 14 | 745-mum-2009-form 1.pdf | 2018-08-10 |
| 14 | 745-MUM-2009-FORM 2(TITLE PAGE)-(29-9-2009).pdf | 2018-08-10 |
| 15 | 745-mum-2009-description(provisional).pdf | 2018-08-10 |
| 15 | 745-MUM-2009-FORM 2(TITLE PAGE)-(PROVISIONAL)-(30-3-2009).pdf | 2018-08-10 |
| 16 | 745-mum-2009-form 2(title page).pdf | 2018-08-10 |
| 17 | 745-MUM-2009-DESCRIPTION(COMPLETE)-(29-9-2009).pdf | 2018-08-10 |
| 17 | 745-mum-2009-form 2.pdf | 2018-08-10 |
| 18 | 745-MUM-2009-CORRESPONDENCE(IPO)-(HEARING NOTICE)-(30-8-2016).pdf | 2018-08-10 |
| 18 | 745-mum-2009-form 26.pdf | 2018-08-10 |
| 19 | 745-MUM-2009-CORRESPONDENCE(IPO)-(FER)-(10-1-2014).pdf | 2018-08-10 |
| 19 | 745-mum-2009-form 3.pdf | 2018-08-10 |
| 20 | 745-MUM-2009-FORM 5(29-9-2009).pdf | 2018-08-10 |
| 20 | 745-MUM-2009-CORRESPONDENCE(IPO)-(26-8-2009).pdf | 2018-08-10 |
| 21 | 745-MUM-2009_EXAMREPORT.pdf | 2018-08-10 |
| 21 | 745-MUM-2009-CORRESPONDENCE(26-9-2009).pdf | 2018-08-10 |
| 22 | 745MUM2009_CS.pdf | 2018-08-10 |
| 22 | 745-MUM-2009-CLAIMS(29-9-2009).pdf | 2018-08-10 |
| 23 | 745MUM2009_reply to ER.pdf | 2018-08-10 |
| 23 | 745-MUM-2009-ABSTRACT(29-9-2009).pdf | 2018-08-10 |